Promising therapeutic approaches for relapsed/refractory multiple myeloma
1Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Hematology (Amsterdam, Netherlands)
|March 15, 2022
Summary
New therapies like CAR T-cell therapy and antibody-drug conjugates offer hope for relapsed/refractory multiple myeloma (RRMM) patients. Optimal treatment selection requires careful consideration of individual patient factors and therapy side effects.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Relapsed/refractory multiple myeloma (RRMM) presents complex treatment challenges.
- Patients refractory to standard therapies have limited options and poor prognoses.
- Emerging treatments offer new hope but require integration strategies.
Purpose of the Study:
- To review the latest trends and developments in therapies for RRMM.
- To analyze recent clinical data and new drug development technologies.
- To provide an overview of emerging treatments for RRMM.
Main Methods:
- Searched PubMed, Embase, and Cochrane Library for eligible studies.
- Reviewed clinical data of promising new treatments.
- Summarized key results from recent clinical trials.
Main Results:
- Included 13 studies on anti-BCMA CAR T-cell therapy, combined CAR T-cell therapy, antibody-drug conjugates, bispecific antibody therapy, and CELMoDs.
- Summarized key efficacy and side effects of these novel treatments.
- Identified CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates, and PROteolysis Targeting Chimeras as promising next-generation therapies.
Conclusions:
- Emerging treatments provide more options for RRMM patients.
- Optimal therapy selection depends on disease factors, prior treatments, and patient comorbidities.
- Next-generation therapies show great promise for improving outcomes in RRMM.
Keywords:
Bromodomain and extra-terminal proteinsCAR NK-cellCAR T-cellCELMoDsPROteolysis Targeting ChimerasRelapsed/refractory multiple myelomaantibody–drug conjugatesbispecific antibodiesMore Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.2K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
Related Concept Videos
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:27Tumor Immunotherapy
702
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
702